Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents

被引：8
|
作者：
Rizzo, Renata [1 ]
Martino, Davide [2 ,3 ]
机构：
[1] Univ Catania, Neuropsichiatria Infantile, Dipartimento Sci Med & Pediat, I-95123 Catania, Italy
[2] Kings Coll Hosp NHS Fdn Trust, Dept Neurol, London, England
[3] Queen Elizabeth Hosp, Lewisham & Greenwich NHS Trust, London, England
来源：
EXPERT REVIEW OF NEUROTHERAPEUTICS | 2015年 / 15卷 / 04期
关键词：
alpha(2)-adrenoreceptor agonist; attention deficit hyperactivity disorder; guanfacine extended-release; guanfacine immediate-release; treatment; EXTENDED-RELEASE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; OPEN-LABEL; LONG-TERM; PHASE-I; ADHD; PHARMACOKINETICS; PSYCHOSTIMULANTS; NEUROBIOLOGY;
D O I：
10.1586/14737175.2015.1028370
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Guanfacine is an (2A)-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and adolescents, mainly focusing on the use of guanfacine extended-release (GXR). Six already published prospective randomized controlled trials (RCTs) and one unpublished RCT study were identified for GXR in the treatment of ADHD. All RCTs trials showed superiority over placebo on the primary outcome measure. Guanfacine, especially XR, seems to be an effective and safe treatment option for ADHD in children and adolescents.
引用
收藏
页码：347 / 354
页数：8
相关论文
共 50 条
  • [31] Attention deficit hyperactivity disorder (ADHD) in children and adolescents
    Said, Zead
    Huzair, Hifzi
    Helal, Muhammad Nabeel
    Mushtaq, Imran
    [J]. PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2015, 19 (03) : 16 - 23
  • [32] Attention Deficit-Hyperactivity Disorder in Children and Adolescents
    Feldman, Heidi M.
    Reiff, Michael I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (09): : 838 - 846
  • [33] Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
    Findling, Robert L.
    McBurnett, Keith
    White, Carla
    Youcha, Sharon
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2014, 24 (05) : 245 - 252
  • [34] Attention deficit hyperactivity disorder and enuresis in children and adolescents
    Zavadenko N.N.
    Kolobova N.M.
    Suvorinova N.Yu.
    [J]. Neuroscience and Behavioral Physiology, 2011, 41 (5) : 525 - 531
  • [35] Attention-deficit/hyperactivity disorder in children and adolescents
    Dunn, DW
    Kronenberger, WG
    [J]. NEUROLOGIC CLINICS, 2003, 21 (04) : 933 - +
  • [36] Amphetamines for attention deficit hyperactivity disorder in children and adolescents
    Feldman, Mark E.
    [J]. PAEDIATRICS & CHILD HEALTH, 2017, 22 (05) : 288 - +
  • [37] Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
    Newcorn, Jeffrey H.
    Huss, Michael
    Connor, Daniel F.
    Hervas, Amaia
    Werner-Kiechle, Tamara
    Robertson, Brigitte
    [J]. JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2020, 41 (07): : 565 - 570
  • [38] Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    Carbray, Julie A.
    [J]. JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2018, 56 (12) : 7 - 10
  • [39] Venlafaxine in children and adolescents with attention deficit hyperactivity disorder
    Mukaddes, NM
    Abali, O
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (01) : 92 - 95
  • [40] Treatment of attention deficit hyperactivity disorder in children
    Kehoe, WA
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1130 - 1134
12345